Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India And Brazil Sustain Branded Generics Success For Torrent In Q2

All Eyes Are On The German Market, Which Continues To Inhibit Revenues And Strategic Aims

Executive Summary

Torrent continues its overall growth trajectory in Q2 of its 2023 financial year, but a flagging German market slows the company’s expansion strategy. The board insists improved sales are just around the corner.

You may also be interested in...

Torrent’s Brazil Growth Surges 36% In Q3

Torrent’s quarterly revenues were up by 18% to INR24.9bn in Q3 FY2023. Branded generics and the Brazilian market did much of the heavy lifting.

US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance

While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts